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Macrophages are highly plastic hematopoietic cells with diversified functions related to their anatomic location and
differentiation states. A number of recent studies have examined the role of macrophages in solid organ transplantation.
These studies show that macrophages can induce allograft injury but, conversely, can also promote tissue repair in
ischemia-reperfusion injury and acute rejection. Therapeutic strategies that target macrophages to improve outcomes in
solid organ transplant recipients are being examined in preclinical and clinical models. In this review, we discuss the role
of macrophages in different types of injury and rejection, with a focus on macrophage-mediated tissue injury, specifically
vascular injury, repair and remodeling. We also discuss emerging macrophage-centered therapeutic opportunities in
solid organ transplantation.
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Macrophages are ancient cells in metazoan phylogeny
that play critical roles in detecting and eliminating
harmful pathogens. They were first identified and de-
scribed more than a century ago by Élie Metchnikoff [1]
and are an essential component of the innate immune
system, forming the first line of defense against infectious
agents [2,3]. In response to pathogens, macrophages accu-
mulate in tissues both through the recruitment and differ-
entiation of circulating monocytes as well as through in
situ proliferation [4,5]. There, they bind to Toll-like recep-
tor (TLR) ligands such as lipopolysaccharide (LPS) or
interferon-γ (IFN)-γ and are induced into an activation
state that is characterized by a shift from aerobic metabol-
ism to anaerobic glycolysis, increased production of proin-
flammatory mediators, augmented expression of inducible
nitric oxide synthase (iNOS) and synthesis of reactive oxy-
gen (ROS) and nitrogen species (RNS). This phenotype
leads to efficient digestion of engulfed pathogens and is
known as the classically-activated macrophage (CAM)
[3,6]. In addition to their participation in host defense,
macrophages have also been shown to play key roles in a
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unless otherwise stated.homeostasis, tissue repair, as well as pathologic processes
including fibrosis, obesity and malignancy. These macro-
phages are induced by exposure to interleukin (IL)-4 and
IL-13 and have a phenotype that is different from the
CAMs. They are classified as alternatively-activated
macrophages (AAMs) [2,3,6-9]. Finally, the regulatory
macrophage (Mreg) has been recognized for its anti-
inflammatory properties [10] and may play a protective
role in transplant recipients.
CAMs and AAMs are routinely classified as ‘M1’ and
‘M2’ respectively [9]. However, they display tremendous
heterogeneity, changing their phenotypes dramatically in
response to cues from the microenvironment. To ad-
dress these different phenotypes, M2-polarized macro-
phages have been sub-classified into M2a, M2b and M2c
to discriminate their differentiation status in recent years
[11]. In reality, even this more recent classification
scheme does not clearly represent the very wide array of
macrophage types manifesting highly diverse functions
and phenotypes. While a more detailed classification of
macrophages based on gene expression profiles or differ-
entiation status will facilitate target identification for
therapeutic interventions in various pathological condi-
tions [2,9], the fact that macrophages are so highly mut-
able is a persistent consideration in scientific explorations
of these cells. A recent landmark study evaluating the
transcriptome of human macrophages induced by a var-
iety of stimuli revealed an extraordinary spectrum of
macrophage activation states that far extend the currenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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this review generally avoids the M classification scheme
and focuses instead on macrophage phenotype and
function.
It has been recognized since the 1970s that macro-
phages are involved in the rejection of solid organ trans-
plants [13,14]. Macrophages have been shown to play a
role in cell- and antibody-mediated rejection as well as
in the development of graft vascular disease (GVD), a
manifestation of chronic rejection [15,16]. Macrophages
may promote the development of acute rejection by pro-
ducing ROS, eicosanoids and cytokines such as IL-1,
tumor necrosis factor (TNF)-α and IL-18 [17,18]. On the
other hand, macrophages may also dampen the alloim-
mune response by acquiring a regulatory phenotype that
has been recently described [18]. Lastly, monocytes/mac-
rophages may also help repair injured allograft microvas-
culature by producing proangiogenic factors [19].
Currently, immunosuppressive therapy regimens in
organ transplantation primarily target T cells. As trans-
plant outcomes continue to be suboptimal [20,21], iden-
tification and characterization of macrophages with
distinct phenotypes may provide novel therapeutic tar-
gets to improve transplant survival. In this review, we
will highlight studies that provide new insights into the
role that macrophage play in different types of allograft
injury and rejection and conclude with potential thera-
peutic strategies to promote allograft health.
Macrophages in ischemia reperfusion injury (IRI)
Ischemia – reperfusion describes the condition of an
organ during the procurement and transplantation
process. When an organ is harvested, the blood flow to
the organ is cut off and cooled with physiologically-
buffered solution - a state known as cold ischemia. Re-
perfusion occurs after the organ is transplanted and
blood perfusion and oxygenation is restored. Reperfusion
exacerbates the initial ischemia-induced tissue injury by
triggering adaptive and innate immune responses [22]
including macrophages (as described in greater detail
below). The pathophysiological features of IRI include:
1) impaired endothelial barrier function with increased
vascular permeability and leakage, 2) promotion of donor
cell death programs, including apoptosis, autophagy-
induced cell death and necrosis, 3) transcriptional repro-
gramming of donor cells, by upregulation of hypoxia
inducible factor (HIF) and nuclear factor κB (NF-κB)- in-
duced gene expression, 4) activation of the complement
system and 5) activation of TLRs on macrophages and
donor parenchymal cells [22-25].
IRI of the transplanted organ has long been recognized
as a non-allogeneic factor that influences graft function
and survival [26] and macrophages are key components
of this pathology [22]. Macrophages have been shown toaccumulate during the early phase of IRI in kidney and
liver transplants [27,28]. Recently, it was shown that in-
hibition of sphingosine kinase-2 (SK-2) led to decreased
macrophage accumulation in liver transplants, an effect
that correlated with attenuated graft IRI [29]. In cardiac
transplantation, decreased infiltration of macrophages
during IRI also correlated with improved microvascular
health and graft survival [30]. Also, alveolar macro-
phages are thought to be essential in the initiation of IRI
in lung transplantation. They have been shown to induce
tissue injury through the production of ROS and proin-
flammatory cytokines including IL-8, IL-12, IL-18, TNF-
α and platelet activating factor (PAF) [31]. Furthermore,
it has been demonstrated that increased macrophage
recruitment into rat lung allografts induced by IRI is as-
sociated with impaired endothelial cell (EC) barrier func-
tion, and EC injury can be diminished when macrophage
infiltration is decreased [32]. These studies provide com-
pelling evidence that macrophages play a deleterious role
in IRI and contribute to microvascular EC injury follow-
ing transplantation. Moreover, macrophages accumu-
lated during IRI may also help boost and maintain the
adaptive T cell response by producing proinflammatory
mediators and by acting as antigen presenting cells [33].
TLR signaling has been shown to be essential for
macrophage activation [34]. In a study of spinal cord in-
jury, it was shown that TLR4 deficiency protected the
spinal cord from IRI in mice. This study went on to
show that hypoxia and deprivation of glucose induced
TLR4 expression on macrophages and that TLR4-
deficient macrophages produced much lower levels of
TNF-α and IL-6 [35]. These findings suggest a mechan-
ism for TLR4-dependent macrophage-induced IRI. In a
cardiac IRI study, TLR4-dependent, high-mobility group
box-1 (HMGB-1)-activated macrophages produce IL-23,
which in turn induced IL-17 production and caused
heart allograft injury [36]. This result provides a mech-
anistic link between macrophages and IL-17-mediated
IRI. In brain IRI, peroxiredoxin family proteins were also
shown to induce IL-23 production in macrophages
through activation of TLR2 and TLR4 signaling [37].
These recent studies from both the transplant and non-
transplant animal models further demonstrate that acti-
vation of macrophage TLRs is required for macrophage-
induced IRI and suggest that TLR-mediated macrophage
activation likely contributes to IRI in newly-transplanted
organs.
While macrophages have been shown to be harmful
and cause allograft injury, they have also been shown to
play a reparative role in both transplant and non-
transplant IRI. In kidney, a macrophage-specific deletion
of wnt7b significantly hindered tissue repair and regen-
eration following IRI [38]; this study suggests that wnt7b
may also play a protective role in organ transplantation.
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shown that colony stimulating factor-1 (CSF-1), a hema-
topoietic growth factor, promotes tissue repair by enhan-
cing tubular cell proliferation and diminishing its
apoptosis and that this effect partially depends on the
function of macrophages [39]. In lung allografts,
polarization of macrophages by prednisone precondi-
tioning diminished IRI and prolonged graft survival [40],
suggesting that macrophages with an anti-inflammatory
phenotype may also be beneficial during the late stage of
IRI. Another recent study showed that treatment with
human umbilical cord-derived stromal cells reduces
renal IRI and that the beneficial effect depends not only
on the presence of macrophages, but also on polariza-
tion in the later repair phase [41]. This result further
supports the notion that in contrast to the deleterious
effect of infiltrating macrophages seen in early IRI (1-
3 days post transplant), Macrophages may act in a repara-
tive role in late IRI (3-5 days) [42]. The leukotriene B4
receptor type-1 (BLT1) was recently shown to facilitate
macrophage recruitment to the IR injured liver and BLT1
deficiency leads to decreased EGF production and im-
paired tissue repair [43], suggesting a role of macrophage-
produced growth factor in tissue regeneration. These
studies collectively demonstrate that phenotypically-
distinct macrophages exist in different IRI phases and
differential targeting strategies, such as depletion or
phenotypic polarization, are needed to harness the macro-
phage as a therapeutic target to prevent or attenuate IRI
in solid organ transplants.
Macrophages in acute allograft rejection
Acute rejection (AR) is a result of the alloimmune attack
against the graft and is characterized by an inflammatory
pathology that is generally reversible with early immuno-
suppressive intervention [33]. EC injury and vascular
damage is a well-known phenomenon in AR [44,45] and
macrophages are increasingly appreciated as an import-
ant player in both cellular and antibody-mediated AR
[16]. Here we first highlight recent advances in macro-
phage biology in the setting of solid organ transplant-
ation and then discuss in detail how the ECs of the
allograft microvasculature can be damaged as well as
repaired by different types of macrophages during AR.
In a clinical study, CD68+ macrophages but not T cell
infiltration was shown to be associated with renal allo-
graft dysfunction during AR [46]. Consistent with this
finding, a pre-clinical study of kidney transplantation
showed that macrophage depletion with liposomal-
clodronate significantly attenuated graft damage during
AR [47]. More recently, inhibition of Rho kinase was
demonstrated to promote allograft function and this
beneficial effect was associated with decreased macro-
phage infiltration in renal transplants [48]. Additionally,intravascular macrophage accumulation has been ob-
served in cardiac allografts undergoing antibody-
mediated rejection [49]. Furthermore, the accumulation
of intravascular macrophages in early human cardiac
transplantation also predicts the presence of donor spe-
cific antibodies (DSA), C4d deposition and symptoms of
antibody-mediated rejection [50]. Collectively, these
studies suggest that macrophages play an important role
in both cellular and antibody-mediated rejection.
As stated above, macrophages accumulate within a tis-
sue by recruitment of monocytes from the circulation
and through proliferation of resident cells. The mecha-
nisms associated with macrophage accumulation in solid
organ transplants have been extensively studied. CD99
expressed on ECs is required for monocyte migration
through EC junctions [51] and EC expression of P-
selectin is also needed for macrophage accumulation in
cardiac allografts during antibody-mediated rejection
[52], suggesting that EC expression of adhesion mole-
cules is required for monocyte/macrophage extravasa-
tion and subsequent tissue accumulation. Chemokines
such as monocyte chemoattractant protein-1 (MCP-1),
macrophage colony-stimulating factor (M-CSF, also
known as CSF-1) and macrophage migration inhibitory
factor (MIF) were shown to be positively associated with
the number of infiltrated CD68+ or ED1+ macrophages
in renal allografts [53-56]; additionally, chemokine re-
ceptors such as CX3C chemokine receptor 1 (CX3CR1),
CC chemokine receptor 5 (CCR5) and CXC chemokine
receptor 3 (CXCR3) have also been shown to mediate
macrophage recruitment in renal grafts [57,58]. Interest-
ingly, while the RANTES/CCR5 pathway also contrib-
utes to macrophage accumulation in cardiac transplants,
CCR5 blockade only modestly prolonged allograft sur-
vival likely because the recruitment of regulatory T cells
also requires this signaling pathway [59,60]. These stud-
ies collectively demonstrate that multiple chemokines
are involved in the recruitment of macrophages into al-
lografts during AR and blocking chemokine-induced
signaling pathways may be a promising therapeutic strat-
egy. Other studies have shown that local macrophages
proliferate in AR [55,56,61], suggesting another mechan-
ism for increasing the number of macrophages in allo-
grafts undergoing AR.
Once in the allograft, macrophages have been shown
to promote inflammation, induce tissue damage and se-
crete inflammatory mediators. CAMs have been shown
to produce ROS and RNS, which are probably the pri-
mary mediators of tissue damage in AR [47,62-67]. Cyto-
kines such as IL-1β, IL-12, IL-18, TNF-α and IFN-γ have
also been shown to be secreted by macrophages. These
cytokines not only activate ECs and promote cytotoxic T
cell generation, but also induce the production of che-
mokines such as CSF-1 and MCP-1 [68].
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EC injury is relevant to transplantation, it is useful to
consider several lines of evidence demonstrating the
relevance of microvascular health in allograft function
and why macrophage injury to the microvasculature
may negatively affect the transplant. In a mouse orthoto-
pic tracheal transplantation model, our group has shown
that EC death and loss of the graft microvasculature dur-
ing AR precedes (and is likely a key driver for) the devel-
opment of airway fibrosis (i.e. chronic rejection) [69].
We subsequently demonstrated that the activation of the
complement system and CD4+ T cells (but not CD8+ T
cells) independently induces airway microvascular loss
following transplantation [70]. We also showed that
donor cell-expressed HIF-1α is associated with airway
microvascular health and augmented expression of HIF-
1α using adenovirus-mediated gene transfer prolongs EC
survival, promotes vascular repair, and results in delayed
and attenuated airway fibrosis [19]. These data are con-
sistent with clinical studies which show that microvascu-
lar loss precedes and, consequently, may play a causal
role in chronic rejection [71-74]. This concept empha-
sizes the importance of understanding how microvascu-
lar ECs are injured and developing new therapeutic
targets to protect them during AR. Macrophages have
been shown to induce EC apoptosis through activation
of the Wnt pathway in patterning the eye vasculature
during development [75]. Macrophages can also induce










Figure 1 Macrophages and graft vasculature. During acute rejection, m
ROS, RNS, TNF-α and possibly LTB4. On the other hand, macrophages can also
factors, such as VEGF, FGF-2, SDF-1 and PLGF. During chronic rejection, macro
IL-1, TGF-β and possibly LTB4. Abbreviations: IFN, interferon; ROS, reactive oxyg
PDGF, platelet-derived growth factor; IL, interleukin; TGF, transforming growth
vascular endothelial growth factor; FGF, fibroblast growth factor; SDF, stromalrecently demonstrated that the lipid mediator leukotri-
ene B4 (LTB4) produced by macrophages in pulmonary
hypertension lungs induced EC apoptosis; LTB4 was
found to induce significant EC apoptotic death in a
dose-dependent manner within 24 hours of culture [77].
By extension, it is possible that macrophage- produced
LTB4 may also induce allograft EC apoptosis during AR.
Thus, macrophages may directly or indirectly induce EC
death through production of cytotoxic molecules or pro-
inflammatory mediators during AR (Figure 1).
Despite the injurious effects on ECs, macrophages
have also been shown to promote vessel growth in tu-
mors [78-80] and angiogenesis in the hind limb ischemia
model [81]. These macrophages are identified by expres-
sion of the Tie2 receptor. In the airway transplantation
model, our group has also shown that Tie2-expressing
monocytes/macrophages contribute to donor micro-
vascular repair during AR [19]. Tie2-expressing mono-
cytes/macrophage may promote graft microvascular
repair by producing proangiogenic growth factors such
as vascular endothelial cell growth factor (VEGF), pla-
cental growth factor (PLGF), stromal cell-derived factor
(SDF)-1 and fibroblast growth factor (FGF)-2 [19,82]. In
addition, increased expression of HIF through Von Hip-
pel–Lindau (VHL) knockdown in recipient derived Tie2
lineage cells promotes donor vascular regeneration and
limits graft invasion by aspergillus [83]. These studies
suggest that during AR, a subpopulation of macrophages
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en species; RNS, reactive nitrogen species; TNF, tumor necrosis factor;
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cell-derived factor; PLGF, placental growth factor.
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is needed for efficient therapeutic targeting. Figure 1
demonstrates the myriad of effects that graft-infiltrating
macrophages may have on donor microvessels and
arteries.
In addition to graft-protective functions likely con-
ferred by angiogenic macrophages, macrophages with
regulatory function capable of quelling maladaptive
inflammation likely serve a protective role in transplant-
ation. Research in the last decade has identified numer-
ous mechanisms that can induce Mregs both in vitro
and in preclinical animal models [11], including macro-
phage stimulation by M-CSF, IL-10, vitamin D3, gluco-
corticoids and prostaglandin E2 [84-88] as well as
macrophage repetitive stimulation by TLRs [89,90]. The
human Mreg has also recently been generated by cultur-
ing CD14+ peripheral blood monocytes for 7 days in the
presence of M-CSF and 10% human serum plus a 24-
hour IFN-γ pulse [91]. These Mregs have been shown to
be able to potently suppress T cell proliferation through
IFN-γ-induced indoleaminepyrrole 2,3-dioxygenase (IDO)
production and contact-dependent depletion of activated
T cells [92]. In addition, a recent in depth phenotypic and
functional characterization of the mouse Mregs revealed
that these cells belong to a subset of suppressor macro-
phages expressing markers that distinguish them from the
M1- and M2-polarized states [93]. In vitro, these Mregs
completely suppress polyclonal T cell proliferation in an
iNOS-dependent and allospecific fashion and administra-
tion of in vitro-derived Mregs significantly reduces acute
rejection and prolongs the survival of the mouse cardiac
allografts [93]. This study suggested that macrophages
may also protect the vascular EC by differentiating into a
regulatory subtype and consequently suppressing alloreac-
tive T cells. This study also demonstrated that Mregs may
be produced in vitro and could potentially be used as a
source of cellular therapy for tolerance induction with a
reduced dosage of immunosuppressive drugs in solid
organ transplantation.
Macrophages in GVD
Chronic rejection is the leading cause of graft rejection,
which is manifested by transplant tissue fibrosis and/or
GVD [15,19,33]. GVD is the single most important limita-
tion to long-term survival of transplanted solid organs
[15]. It is traditionally seen in the arterioles and the arteries
and may affect the entire length of the arterial vasculature
in transplants. It is characterized by a concentric vascular
intimal lesion comprised of smooth muscle-like cells
(SMLC) and abnormally laid extracellular matrix and may
simply be considered a result of abnormal stereotypic heal-
ing following alloimmune induced vascular injury [15,94].
Numerous studies show that macrophages are associ-
ated with the development of GVD; these cells havebeen observed in the lesions of GVD [95-99]. Macro-
phage depletion, but not inhibition of their ability to
phagocytose, suppressed the development of cardiac
graft vascular disease [100], suggesting that macrophages
likely promote GVD through the production of proin-
flammatory, cytotoxic and trophic mediators but not
their function as antigen-presenting cells. A study in kid-
ney transplants showed that treatment with a macrophage
inhibitor prevented progressive glomerulosclerosis, inter-
stitial fibrosis, and arterial obliteration [101]. A more re-
cent clinical study revealed that in heart transplants with
very late rejection (> 7 years following transplantation),
the presence of intravascular macrophages and donor spe-
cific antibodies are robust predictors of the development
of more severe GVD [102]. Therapies effective in reducing
GVD have also been shown to be associated with a signifi-
cantly deceased macrophage infiltration [103,104]. These
recent studies further confirmed that macrophages play a
role in the pathogenesis of GVD.
Numerous mechanisms have been identified by which
macrophages may promote the development of GVD.
They may act as the predominant effector cells in CD4+
T cell-mediated delayed type hypersensitivity and have
been shown to induce tissue and vascular damage
through the production of eicosanoids, deleterious pro-
teases, ROS and nitric oxide [15]. Macrophages may also
promote GVD through the production of proinflamma-
tory cytokines including IL-1, TNF-α, IFN-γ, platelet-
derived growth factor (PDGF) and transforming growth
factor (TGF)-β [15] (Figure 1). Double knockouts of
both TNF-α receptor-1 and -2 in the graft significantly
attenuated GVD in heart transplants [105], suggesting
that TNF-α mediated signaling also contributes to the
development of GVD. IFN-γ is also an important cyto-
kine in the development of chronic rejection. In a heart
transplant model, IFN-γ was shown to be both necessary
and sufficient to drive the development of GVD [106].
Following IFN-γ stimulation, it has also been shown that
macrophages produce IL-12 and IL-18, which further ac-
tivates CD4+ T cell production of IFN-γ, thus forming a
positive feedback loop [107]. Additionally, SMLCs also
produce IFN-γ following IL-12 and IL-18 stimulation
[108], demonstrating that macrophages and SMLCs may
work together to promote the development of GVD.
SMLCs that display a synthetic phenotype are the pri-
mary cells that populate the lesions of GVD [15]. SMLCs
with both donor and recipient origins have been de-
scribed [109,110]. Numerous chemokine receptors in-
cluding CXCR3, CXCR4, CCR1, CCR2, CCR3 and CCR5
are expressed on SMLCs [111-114]. Thus, macrophages
producing cognate chemokines may promote recruit-
ment and retention of recipient derived SMLCs, which
may then facilitate neointimal formation and the devel-
opment of GVD [15,94,115]. In an endothelial injury
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group showed that macrophages are the prominent pro-
ducers of LTB4 (described above) and, in addition to
causing EC apoptosis, also promote vascular smooth
muscle cell proliferation and vascular remodeling. Block-
ade of LTB4 production by inhibition of the enzyme
LTA4 hydrolase efficiently reopens obstructed pulmonary
arterioles and reverses severe pulmonary arterial hyper-
tension [77]. Together, these studies suggested that
blockade of the chemokine signaling involved in macro-
phage recruitment and its production of the proinflam-
matory mediator may prevent/reverse GVD.
Of note, despite increasing appreciation that micro-
vascular loss in solid organ transplants may play a causal
role in the development of graft fibrosis and chronic re-
jection [19,30,69,71-74], GVD does not describe the
pathology of the capillary loss and subsequent abnormal
angiogenesis (e.g. microvascular loss in the airway trans-
plant undergoing rejection as we described [19]). Inter-
estingly, we recently found that macrophage infiltration
is nearly absent around the remodeled capillaries of the
chronically rejected airway transplants (unpublished ob-
servation). It is therefore possible that macrophages may
only have significant effects on the microvasculature
during IRI and AR.
Concluding remarks
Macrophages, historically thought of as ‘accessory cells’
with a poorly-described secondary function, are now
emerging as an important cell type in solid organ trans-
plantation. Compelling preclinical and clinical studies
have shown that macrophages not only promote graft
injury and GVD, but also participate in tissue repair, in-
cluding microvascular repair, in different types of trans-
plant related injury. Strategies for macrophage-centered
therapeutics may include macrophage depletion or
polarization to a reparative phenotype. Depletion may be
achieved by direct killing through antagonism of CSF-1R
or CSF-1 [85] or by blockade of recruitment by targeting
CCR and CXCR mediated chemotactic pathways
[57-60,116-118]. In transplantation rejection, when in-
jurious and reparative classes coexist within the allograft,
polarization of macrophages to a reparative phenotype
may be a better strategy. Indeed, commonly used im-
munosuppressive drugs, such as glucocorticoids and
mammalian target of rapamycin (mTOR) inhibitors, in
addition to antagonizing T cells, are known to polarize
macrophages to a suppressive phenotype [119,120].
More recently, ex vivo expanded regulatory macrophages
were characterized and used in clinical trials, which may
represent a promising therapeutic modality to prolong
graft survival [92].
In summary, macrophages play numerous roles in
solid organ transplant injury and rejection. A betterunderstanding of how macrophages both damage and
repair the allograft circulatory system in different types
of transplant injury and rejection is required to further
promote this cell, in all its myriad manifestations, as a
promising therapeutic target. With advances in the fields
of genomic analysis and systems biology, an improving
delineation of macrophage subtypes is already occurring
and opening new doors of investigation.
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